Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.
Saurabh Dahiya, MD, FACP
Advertisement
Saurabh Dahiya, MD, FACP, is an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Articles by Saurabh Dahiya, MD, FACP
Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.
Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.
Drs Dahiya and Patel discuss how SPC research may help optimize CAR T-cell product development in the future.
Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
Advertisement
Latest Updated Articles
How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhDPublished: January 30th 2025 | Updated:
Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell LymphomaPublished: June 13th 2025 | Updated:
Dr Dahiya on the Pathobiology of Second Primary Cancers After CAR T-Cell TherapyPublished: January 31st 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5